Summary
Catalyst Bio succeeds in Phase 2/3 trial.
CTI plans to launch Phase 3 trial.
Pfizer announces successful Phase 3 data.
This idea was discussed in more depth with members of my private investing community, The Total Pharma Tracker.
Stocks in News: CBIO, CTIC
Catalyst Bio's marzeptacog alfa shows positive action in hemophilia study
Discussion: Catalyst Biosciences (CBIO) announced interim data from a Phase 2/3 clinical trial of evaluating subcutaneously administered prophylactic Factor VIIa variant marzeptacog alfa (activated) in patients with hemophilia A or B with inhibitors. One administered patient showed significant improvement in prevention of bleeding in the first 96 days. Two other patients are yet to complete the first 50 days of dosing to determine any significant improvement. Marzeptacog alfa's subcutaneous half life is 9.5 or almost three times the intravenous half life of 3.5.
